SCHEMBL4028367

SCHEMBL4028367

Cn1c(-c2sccc2NC(=O)OCc2ccccc2Cl)nc(C(=O)O)c(O)c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.47
FEN1 P39748 1/20 0.47
ERCC4 Q92889 1/20 0.47
MEN1 O00255 1/20 0.44
PKM P14618 1/20 0.44
CASP3 P42574 1/20 0.44
KMT2A Q03164 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
SCN9A Q15858 2/20 0.40
SCN5A Q14524 1/20 0.40
PTGDR2 Q9Y5Y4 2/20 0.39
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
HTT P42858 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
CYP1A2 P05177 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4028369 0.89 MEN1 (0.43) ERCC1FEN1ERCC4MEN1PKM
SCHEMBL4031788 0.88 MEN1 (0.41) ERCC1FEN1ERCC4MEN1PKM
SCHEMBL4027671 0.86 ERCC1 (0.47) ERCC1FEN1ERCC4MAPK8MAPK10
SCHEMBL4029613 0.86 ERCC1 (0.47) ERCC1FEN1ERCC4MEN1KMT2A
SCHEMBL4026222 0.82 ERCC1 (0.49) ERCC1FEN1ERCC4MAPK8MAPK10
SCHEMBL4028016 0.80 FEN1 (0.58) ERCC1FEN1ERCC4MAPK8MAPK10
SCHEMBL4030403 0.79 ERCC1 (0.56) ERCC1FEN1ERCC4MEN1KMT2A
SCHEMBL4027570 0.78 ERCC1 (0.55) ERCC1FEN1ERCC4MEN1PKM
SCHEMBL4028503 0.78 ERCC1 (0.46) ERCC1FEN1ERCC4MAPK8MAPK10
SCHEMBL4029947 0.77 ERCC1 (0.47) ERCC1FEN1ERCC4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1470113-B1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ANGELETTI P IST RICHERCHE BIO (IT) 2009-01-07 EP claimed
EP-1470113-B1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ANGELETTI P IST RICHERCHE BIO (IT) 2009-01-07 EP disclosed
US-20050130997-A1 Pyrimidinone viral polymerase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2005-06-16 US disclosed
EP-1470113-A1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2004-10-27 EP disclosed
WO-2003062211-A1 PYRIMIDINONE VIRAL POLYMERASE INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130997-A1 Pyrimidinone viral polymerase inhibitors POLR2A, POLR1E, POLR2E ERCC1 3181/4885FEN1 343/4885ERCC4 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.